A neat and smooth way of life, avoiding the acquisition of inadequate health habits, as well as certain foodstuffs, and the sensitivity which can be a cause of neurological disease, including MS, may also be cure for the disease
Such a macrobiotic diet, and low radioactive water (cca 6 Becquerel / Bq) lower temperatures (18-20° C), swimming pool and professionally indicated and controlled use of corticosteroids, symptomatic therapy and immunomodulatory drugs in different phases of the disease, proved to be very useful in many cases the form of RR MS, as evidenced by reports of many research papers, observations, the patients themselves and their medical practitioners.
According to a personal belief, the answer lies largely in already given an introductory explanation to a question. Adding that according “Randomized clinical trials have demonstrated the efficacy of disease - modifying drug (DMDs)- interferon beta-1a, interferon beta-1b, and glatiramer acetate – in relapsing-onset MS … to estimates of disease – modifying drug (DMD) relative treatment effect size, in the context of ‘real-world’ clinical practice, are similar to DMD treatment efficacy estimate in pivotal, though findings attained statistical significance. DMDs are effective in delaying Expanded Disability Status Scale progression in patients with relapsing-onset definite MS (90%), although effectiveness is much better for RRMS than for secondary progressive MS” (Neurology 2007; 69: 1498-1507).
On the clinical question: What is the best current DMDs for RRMS? By info: Neuropsychiatric Disease and Treatment 2010:6 365–373, the research results were: "The evidence shows that the most effective DMD for delaying short- to medium-term disability progression, prevention of relapses, reducing the area and activity of lesions on magnetic resonance imaging, with the least side effects, is high-dose, high-frequency subcutaneous interferon-β1a 44 µg three times per week".
Future research directions on MS treatments include investigations of MS pathogenesis and heterogeneity; research of more effective, convenient, or tolerable new treatments for RRMS; creation of therapies for the progressive subtypes; neuroprotection strategies; and the search for effective symptomatic treatments. Many treatments already in clinical trials involve drugs that are used in other diseases or medications that have not been designed specifically for MS. There are also trials involving the combination of drugs that are already in use for MS. Finally, there are also many basic investigations that try to understand better the disease and in the future may help to find new treatments.
- Badges
- Science topic
- Similar topics
- Chemistry
- Pharmacology
- Pharmaceuticals
- Drugs